YOUR BUSINESS AUTHORITY
Springfield, MO
Merck announced plans to buy Prometheus Biosciences.
The deal is valued at $10.8 billion.
Prometheus Biosciences has an experimental treatment for ulcerative colitis and Crohn's disease, according to CNBC.
Read more from CNBC.
Project work in Springfield corridor will continue into 2031.